Matthew E Kennedy Selected Research

verubecestat

12/2020	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
1/2019	Verubecestat for Prodromal Alzheimer's Disease. Reply.
1/2017	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
12/2016	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
11/2016	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew E Kennedy Research Topics

Disease

13	Alzheimer Disease (Alzheimer's Disease) 12/2020 - 08/2003
5	Parkinson Disease (Parkinson's Disease) 01/2022 - 12/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Wounds and Injuries (Trauma) 01/2020
1	Disease Progression 01/2017
1	Edema (Dropsy) 01/2017
1	Amyloid Plaque 08/2003

Drug/Important Bio-Agent (IBA)

7	Amyloid (Amyloid Fibrils)IBA 01/2018 - 06/2014
5	Phosphotransferases (Kinase)IBA 01/2022 - 12/2015
5	verubecestatIBA 12/2020 - 11/2016
5	Peptides (Polypeptides)IBA 11/2016 - 08/2003
4	Leucine (L-Leucine)FDA Link 01/2022 - 12/2015
3	EnzymesIBA 12/2019 - 08/2003
2	Proteins (Proteins, Gene)FDA Link 12/2016 - 06/2014
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 06/2014 - 08/2003
1	Leucine-Rich Repeat Serine-Threonine Protein Kinase-2IBA 01/2022
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2017
1	AmidesIBA 12/2016
1	Pharmaceutical PreparationsIBA 07/2014
1	Peptide Hydrolases (Proteases)FDA Link 07/2014

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2020
1	Immunotherapy 01/2017